Appendix. Supplementary Materials

SUPPLEMENTARY TABLES

Table S1. CD4/CD8 normalization at cutoff >0.4: Efavirenz vs Maraviroc b.i.d.

N=519	Hazard Ratio (SE)	CI 95%	P value
Model 1. Cox PH Crude model			
Treatment arm (efavirenz vs. maraviroc)	1.25 (0.12)	1.04; 1.55	0.020
Model 2. Adjusted for age, sex, baseline CD4 counts, baseline CD8 counts and HCV status			
Treatment arm (efavirenz vs. maraviroc)	1.30 (0.13)	1.07; 1.58	0.007

Abbreviatures: SE, standard error; CI, confidence interval

Table S2. CD4/CD8 normalization at cutoff >1: Efavirenz vs Maraviroc b.i.d.

N=519	Hazard Ratio (SE)	CI 95%	P value
Model 1. Cox PH Crude model			
Treatment arm (efavirenz vs. maraviroc)	1.42 (0.20)	1.09; 1.87	0.010
Model 2. Adjusted for age, sex, baseline CD4 counts, baseline CD8 counts and HCV status			
Treatment arm (efavirenz vs. maraviroc)	1.43 (0.20)	1.10; 1.88	0.009

Abbreviatures: SE, standard error; CI, confidence interval

Table S3. Longitudinal trajectory of CD4/CD8 ratio per treatment group (generalized estimating equation)

	Coefficient	Standard Error	P value
Intercept	-0.3479	0.000	<0.001
Duration (weeks)	-0.0003	0.000	<0.001
Treatment (maraviroc)	-0.013	0.006	0.034
CD4+ T cell count	0.0007	0.001	<0.001
CD8+ T cell count	-0.0003	0.001	<0.001